Published in J Pediatr on February 01, 2005
Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer (2009) 1.49
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) 1.37
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood (2012) 1.28
Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One (2012) 0.89
Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84
Romiplostim as a treatment for immune thrombocytopenia: a review. J Blood Med (2015) 0.82
Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol (2007) 0.80
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Chronic immune thrombocytopentic purpura in children: assessment of rituximab treatment. J Pediatr (2006) 0.75
Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel) (2015) 0.75
Differential Expression of T-bet and GATA3 in Egyptian Children with Idiopathic Thrombocytopenic Purpura. Indian J Hematol Blood Transfus (2015) 0.75
Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children. J Pediatr (2005) 0.75
Rituximab for chronic immune thrombocytopenic purpura. J Pediatr (2006) 0.75
Rituximab leads to long remissions in patients with chronic immune thrombocytopenia. Oman Med J (2015) 0.75
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Therapeutic action and the analyst's responsibility. J Am Psychoanal Assoc (2014) 4.45
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (2010) 4.20
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol (2011) 3.66
The ITP syndrome: pathogenic and clinical diversity. Blood (2009) 2.83
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol (2010) 2.55
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood (2010) 2.21
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood (2008) 2.13
How I treat idiopathic thrombocytopenic purpura (ITP). Blood (2005) 2.05
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood (2008) 2.03
Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood (2009) 1.96
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood (2011) 1.89
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood (2012) 1.88
Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood (2003) 1.81
Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol (2009) 1.78
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol (2003) 1.70
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood (2008) 1.63
CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med (2007) 1.61
Preventing disability through community-based health coaching. J Am Geriatr Soc (2003) 1.52
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood (2012) 1.50
Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol (2008) 1.45
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol (2004) 1.43
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) 1.37
ANKRD26-related thrombocytopenia and myeloid malignancies. Blood (2013) 1.32
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol (2013) 1.30
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood (2012) 1.28
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol (2003) 1.16
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol (2007) 1.11
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol (2004) 1.10
Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol (2006) 1.10
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.07
Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood (2007) 1.05
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol (2007) 1.03
Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol (2006) 1.02
Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol (2010) 1.01
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol (2011) 1.00
Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant (2004) 1.00
Immune thrombocytopenic purpura. Hematol Oncol Clin North Am (2007) 0.99
Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol (2011) 0.99
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes (2007) 0.98
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol (2008) 0.97
Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood (2011) 0.97
Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia. Pediatr Neurol (2008) 0.96
Proteinuria in children with sickle cell disease. Nephrol Dial Transplant (2007) 0.95
Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica (2010) 0.95
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes (2008) 0.95
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol (2009) 0.94
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood (2013) 0.93
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer (2010) 0.91
Community-based health coaching, exercise, and health service utilization. J Aging Health (2005) 0.91
A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther (2007) 0.90
Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program (2007) 0.90
Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease. Cardiology (2002) 0.90
Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol (2014) 0.89
Primary thrombocytosis in children. Haematologica (2014) 0.89
Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol (2006) 0.88
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica (2014) 0.88
A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood (2007) 0.87
Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr (2008) 0.87
Stability of measurement of the immature platelet fraction. Am J Hematol (2010) 0.87
Advances in the management of alloimmune thrombocytopenia. Br J Haematol (2007) 0.86
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer (2009) 0.84
Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev (2011) 0.84
The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep (2010) 0.84
Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol (2011) 0.83
Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol (2011) 0.83
Benefits of Diabetes Self-Management for Health Plan Members: A 6-Month Translation Study. J Med Internet Res (2016) 0.83
Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma. Cancer Genet Cytogenet (2009) 0.82
Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. Am J Hematol (2007) 0.82
Community-based nurse health coaching and its effect on fitness participation. Lippincotts Case Manag (2004) 0.82
Thrombopoietin-receptor agonists. Curr Opin Hematol (2012) 0.82
Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol (2012) 0.81
Fc receptors in immune thrombocytopenias: a target for immunomodulation? J Clin Invest (2008) 0.81
New thrombopoietic agents: introduction. Semin Hematol (2010) 0.81
The child with immune thrombocytopenic purpura: is pharmacotherapy or watchful waiting the best initial management? A panel discussion from the 2002 meeting of the American Society of Pediatric Hematology/Oncology. J Pediatr Hematol Oncol (2004) 0.81
Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol (2003) 0.80
Thrombopoietic agents in immune thrombocytopenia. Semin Hematol (2010) 0.80
The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol (2008) 0.80
Romiplostim: a second-generation thrombopoietin agonist. Drugs Today (Barc) (2009) 0.80
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. Curr Opin Oncol (2008) 0.79
How low can you go? Blood (2013) 0.78
Maternal and neonatal characteristics associated with neonatal neutropenia in hypertensive pregnancies. Am J Perinatol (2009) 0.78
Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol (2012) 0.78
Novel 47.5-kb deletion in RAB27A results in severe Griscelli Syndrome Type 2. Mol Genet Metab (2010) 0.78
Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. Haematologica (2005) 0.78
Differential diagnosis and management of thrombocytopenia in childhood. Pediatr Clin North Am (2004) 0.78
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol (2014) 0.77
Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology (2011) 0.77
An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. Biol Blood Marrow Transplant (2003) 0.77
Fetal and neonatal alloimmune thrombocytopenia in pregnancies involving in vitro fertilization: a report of four cases. Am J Obstet Gynecol (2005) 0.77
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion (2011) 0.77
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol (2013) 0.76